VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC Internation...(er Center Tampa FL and at the MD Anderso...),Health

Date:10/19/2007

er Center, Tampa, FL and at the MD Anderson Cancer Center, Houston, TX. There are plans to open up more sites and conduct several Phase II studies in various types of tumors using VQD-002 in combination with other chemotherapies and in radiotherapy as well. A previous Phase II clinical trial sponsored by the National Cancer Institute included 21 evaluable patients with cervical cancer, of which 2 responses were observed. One patient had a complete response for 19+ months, another patient had a partial response for 5+ months, and 8 patients had shown stable disease, as observed in their RECIST scores.

About Lenocta(TM)

Lenocta(TM) is an inhibitor of multiple protein tyrosine phosphatases (PTPases), specifically the SRC homology PTPase (SHP-1 & SHP-2) and PTB-1B, based on data from several preclinical studies conducted at the Cleveland Clinic. These intracellular enzymes are involved in signaling pathways of many receptor-linked tyrosine kinases which are involved in growth, proliferation and differentiation of cancer cells. Inhibition of these enzymes with Lenocta(TM) can trigger apoptosis, (programmed cell death) of malignant cells. This antiproliferative and pro-apoptotic effects, coupled with its potential ability to enhance the body's immune system, through improved cytokine signaling, T-cell and dendritic cell functions indicate that Lenocta(TM) has potentials as an anti-cancer agent. It is known that one major mechanism of regulating the growth and proliferation of cancer cells involves activation of cellular pathways, especially protein tyrosine kinase pathways and in particular, the Jak/Stat pathway. It has also been recognized that interferon and other cytokines exert their anti-cancer effects via these pathways.

About VioQuest Pharmaceuticals

VioQuest focuses on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action primarily for oncology and infectious
'/>"/>

SOURCE VioQuest Pharmaceuticals Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation